Abstract
The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 92S-96S |
| Journal | Seminars in Cutaneous Medicine and Surgery |
| Volume | 35 |
| DOIs | |
| State | Published - Jun 1 2016 |
Fingerprint
Keywords
- Atopic dermatitis
- Crisaborole
- Dupilumab
- Interleukin inhibitors
- Petrolatum
- Skin barrier
ASJC Scopus subject areas
- Surgery
- Medicine(all)
- Dermatology
Cite this
Assessing the new and emerging treatments for atopic dermatitis. / Eichenfield, Lawrence F.; Friedlander, Sheila F.; Simpson, Eric; Irvine, Alan D.
In: Seminars in Cutaneous Medicine and Surgery, Vol. 35, 01.06.2016, p. 92S-96S.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Assessing the new and emerging treatments for atopic dermatitis
AU - Eichenfield, Lawrence F.
AU - Friedlander, Sheila F.
AU - Simpson, Eric
AU - Irvine, Alan D.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.
AB - The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.
KW - Atopic dermatitis
KW - Crisaborole
KW - Dupilumab
KW - Interleukin inhibitors
KW - Petrolatum
KW - Skin barrier
UR - http://www.scopus.com/inward/record.url?scp=85014728974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014728974&partnerID=8YFLogxK
U2 - 10.12788/j.sder.2016.043
DO - 10.12788/j.sder.2016.043
M3 - Article
VL - 35
SP - 92S-96S
JO - Seminars in Cutaneous Medicine and Surgery
JF - Seminars in Cutaneous Medicine and Surgery
SN - 1085-5629
ER -